VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Sherwell-Cabello on Prognostic Impact of TILs and SILs in TNBC

Santiago Sherwell-Cabello, MD
Published: Saturday, Sep 26, 2015



Santiago Sherwell-Cabello, MD, breast surgical oncology, Instituto de Enfermedades de la Mama, discusses the prognostic impact of tumor-infiltrating lymphocytes (TILs) and stromal-infiltrating lymphocytes (SILs) in patients with triple-negative breast cancer (TNBC).

Not all patients with TNBC, an aggressive form of breast cancer, respond to neoadjuvant chemotherapy, Sherwell-Cabello explains. A recent study looked at TILs and SILs in these patients to measure their response to neoadjuvant chemotherapy, as well as measure disease-free survival and overall survival.

Results showed that patients with TILs and SILs demonstrate better response rates to neoadjuvant chemotherapy versus those without the lymphocytes, he adds. Patients without TILs and SILs had complete responses (CRs) of 10%, compared to 40% CRs in those with the lymphocytes present.


Santiago Sherwell-Cabello, MD, breast surgical oncology, Instituto de Enfermedades de la Mama, discusses the prognostic impact of tumor-infiltrating lymphocytes (TILs) and stromal-infiltrating lymphocytes (SILs) in patients with triple-negative breast cancer (TNBC).

Not all patients with TNBC, an aggressive form of breast cancer, respond to neoadjuvant chemotherapy, Sherwell-Cabello explains. A recent study looked at TILs and SILs in these patients to measure their response to neoadjuvant chemotherapy, as well as measure disease-free survival and overall survival.

Results showed that patients with TILs and SILs demonstrate better response rates to neoadjuvant chemotherapy versus those without the lymphocytes, he adds. Patients without TILs and SILs had complete responses (CRs) of 10%, compared to 40% CRs in those with the lymphocytes present.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x